| abstract |
REFERS TO THE COMPOUND: ESCITALOPRAM OF FOMULA (S) -1- [3- (DIMETHYLAMINE) PROPYL] -1- (4-FLUORPHENIL) -1,3-DIHYDRO-5-ISOBENZOPHURANCARBONITRILE, WHICH BECOMES THE DIMMER S OF THE COMPOUND CITALOPRAM, SPECIFICALLY REFERRING TO ITS BROMHYDRATE SALT, IN ITS SOLID-CRYSTALLINE FORM. IT ALSO REFERS TO A PREPARATION PROCEDURE AND A PHARMACEUTICAL COMPOSITION CONTAINING ESCITALOPRAM BROMHYDRATE AND ONE OR MORE PHARMACEUTICALLY ACCEPTABLE CARRIERS AND DILUENTS. THIS COMPOUND IS A CENTRAL ACTION INHIBITOR OF THE REABSORPTION OF SEROTONIN AND IS USEFUL FOR THE TREATMENT OF DEPRESSION, WHICH COVERS THE TREATMENT OF PATIENTS WHO DID NOT RESPOND TO THE INITIAL TREATMENT WITH CONVENTIONAL SSRI, NEUROTIC DISORDERS, DISORDERS OF NEUROTIC, IS DISORDERS OF AGES FEEDING SUCH AS BULIMIA, ANOREXIA AND OBESITY, DISTIMIA, PREMENSTRUAL SYNDROME, COGNITIVE DISORDERS, IMPULSE CONTROL DISORDERS, HYPERACTIVITY DISORDERS AND INACTIVE ATTENTION AND DRUG ABUSE |